Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer

References

• Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505.
   PubMed Web of Science ®Google Scholar
• Leal MF, Wisnieski F, De Oliveira GC, et al. What gastric cancer proteomic studies show about gastric carcinogenesis? Tumour Biol. 2016;37:9991–10010.
   PubMedGoogle Scholar
• Ma J, Hong L, Chen Z, et al. Epigenetic regulation of microRNAs in gastric cancer. Digest Dis Sci. 2014;59:716–723.
   PubMed Web of Science ®Google Scholar
• An X, Sarmiento C, Tan T, et al. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7:38–51.
   PubMed Web of Science ®Google Scholar
• Gong J, Jaiswal R, Mathys J-M, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38:226–234.
   PubMed Web of Science ®Google Scholar
• Sakai NS, Samia-Aly E, Barbera M, et al. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23:512–521.
   PubMed Web of Science ®Google Scholar
• Wu Y-R, Qi H-J, Deng D-F, et al. MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer. Tumour Biol. 2016;37:12061–12070.
   PubMedGoogle Scholar
• Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46:298–311.
   PubMed Web of Science ®Google Scholar
• Liang H, Gong F, Zhang S, et al. The origin, function, and diagnostic potential of extracellular microRNAs in human body fluids. Wiley Interdiscip Rev RNA. 2014;5:285–300.
   PubMed Web of Science ®Google Scholar
• Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35–47.
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhang R-W, Sui P-C, et al. Dysregulation of non-coding RNAs in gastric cancer. World J Gastroenterol. 2015;21:10956–10981.
   PubMed Web of Science ®Google Scholar
• Hong L, Yang Z, Ma J, et al. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 2013;14:1118–1127.
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Z, Xia L, et al. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 2014;5:11552–11563.
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33:3267–3276.
   PubMed Web of Science ®Google Scholar
• Zhang X-L, Shi H-J, Wang J-P, et al. MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol. 2015;8:6397–6406.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res. 2011;30:55.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li Y, Tan BB, et al. HIF-1alpha induces multidrug resistance in gastric cancer cells by inducing MiR-27a. PLoS One. 2015;10:e132746.
   Web of Science ®Google Scholar
• Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013;434:688–694.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. Febs Lett. 2013;587:3069–3075.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qu X, Li C, et al. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 2015;36:2277–2285.
   PubMed Web of Science ®Google Scholar
• Zou J, Xu Y. MicroRNA-140 inhibits cell proliferation in gastric cancer cell line HGC-27 by suppressing SOX4. Med Sci Monit. 2016;22:2243–2252.
   PubMed Web of Science ®Google Scholar
• Jin B, Liu Y, Wang H. Antagonism of miRNA-21 sensitizes human gastric cancer cells to paclitaxel. Cell Biochem Biophys. 2015;72:275–282.
   PubMed Web of Science ®Google Scholar
• Li C, Zou J, Zheng G, et al. MiR-30a decreases multidrug resistance (MDR) of gastric cancer cells. Med Sci Monit. 2016;22:4509-4515.
   PubMed Web of Science ®Google Scholar
• Shang Y, Feng B, Zhou L, et al. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget. 2010;1:538–549.
   Google Scholar
• Zhu W, Shan X, Wang T, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127:2520–2529.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhu D, Lu S, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–391.
   PubMed Web of Science ®Google Scholar
• Pan Y, Ren F, Zhang W, et al. Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. Oncol Rep. 2014;32:2549–2556.
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu H, Zhu D, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2012;69:723–731.
   PubMed Web of Science ®Google Scholar
• Sun Z, Song X, Li X, et al. In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale. 2014;6:14343–14353.
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123:372–379.
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. Bmc Cancer. 2008;8:266.
   PubMed Web of Science ®Google Scholar
• Hu J, Fang Y, Cao Y, et al. miR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci. 2014;59:336–345.
   PubMed Web of Science ®Google Scholar
• Kim H, Choi H, Lee SK. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett. 2015;356:733–742.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zuo J, Liu Y, et al. Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chin J Cancer. 2010;29:1006–1011.
   PubMedGoogle Scholar
• Chang L, Guo F, Wang Y, et al. MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res. 2014;20:93–98.
   PubMed Web of Science ®Google Scholar
• Yang S-M, Huang C, Li X-F, et al. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–168.
   PubMed Web of Science ®Google Scholar
• Fang Y, Shen H, Li H, et al. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013;45:963–972.
   PubMed Web of Science ®Google Scholar
• Eto K, Iwatsuki M, Watanabe M, et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2014;21:343–350.
   PubMed Web of Science ®Google Scholar
• Liu N, Zuo C, Wang X, et al. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget. 2014;5:4959–4971.
   PubMed Web of Science ®Google Scholar
• Zhang X-L, Shi H-J, Wang J-P, et al. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol. 2014;20:11347–11355.
   PubMed Web of Science ®Google Scholar
• Yang M, Shan X, Zhou X, et al. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 2014;14:884–891.
   PubMed Web of Science ®Google Scholar
• Zhuang M, Shi Q, Zhang X, et al. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour Biol. 2015;36:2737–2745.
   PubMedGoogle Scholar
• Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and −145 in human gastric cancers. Oncology-Basel. 2009;77:12–21.
   PubMed Web of Science ®Google Scholar
• Wang T, Ge G, Ding Y, et al. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J (Engl). 2014;127:2357–2362.
   PubMed Web of Science ®Google Scholar
• He M, Qian J, Shi Q, et al. miR-497 regulates cisplatin resistance of human gastric cancer cell line by targeting IGF1R, IRS1 and BCL2. J Med Oncol. 2015;2:1–7.
   Google Scholar
• Zhao J, Nie Y, Wang H, et al. miR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene. 2016;576:828–833.
   PubMed Web of Science ®Google Scholar
• An Y, Zhang Z, Shang Y, et al. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6:e1766.
   PubMed Web of Science ®Google Scholar
• Liu X, Ru J, Zhang J, et al. miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. PLoS One. 2013;8:e64707.
   PubMed Web of Science ®Google Scholar
• Xiong H-L, Zhou S-W, Sun A-H, et al. MicroRNA197 reverses the drug resistance of fluorouracilinduced SGC7901 cells by targeting mitogenactivated protein kinase 1. Mol Med Rep. 2015;12:5019–5025.
   PubMed Web of Science ®Google Scholar
• Eto K, Iwatsuki M, Watanabe M, et al. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer. 2015;136:1537–1545.
   PubMed Web of Science ®Google Scholar
• Wang J-X, Li Q, Li P-F. Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynamin-related protein-1. Cancer Res. 2009;69:492–500.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Z, Yu M, et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 2013;14:16226–16239.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhou X, Du Y, et al. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 2016;14:1742–1750.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kong Y, Yang W, et al. Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep. 2016;36:2391–2397.
   PubMed Web of Science ®Google Scholar
• Zhou X, Jin W, Jia H, et al. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 2015;34:28.
   PubMed Web of Science ®Google Scholar
• Teng R, Hu Y, Zhou J, et al. Overexpression of Lin28 decreases the chemosensitivity of gastric cancer cells to oxaliplatin, paclitaxel, doxorubicin, and fluorouracil in part via microRNA-107. PLoS One. 2015;10:e143716.
   PubMed Web of Science ®Google Scholar
• Wen L, Cheng F, Zhou Y, et al. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol. 2015;21:313–319.
   PubMed Web of Science ®Google Scholar
• Deng H, Guo Y, Song H, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518:351–359.
   PubMed Web of Science ®Google Scholar
• Wang P, Li Z, Liu H, et al. MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun. 2016;479:91–96.
   PubMed Web of Science ®Google Scholar
• Shen Q, Yao Q, Sun J, et al. Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. Febs Lett. 2014;588:184–191.
   PubMed Web of Science ®Google Scholar
• Wu H, Huang M, Lu M, et al. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71:1159–1171.
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Sugihara H, Watanabe M, et al. Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. Carcinogenesis. 2014;35:1003–1011.
   PubMed Web of Science ®Google Scholar
• Zhou X, Su J, Zhu L, et al. Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter. 2014;19:174–181.
   PubMed Web of Science ®Google Scholar
• Cao W, Wei W, Zhan Z, et al. MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep. 2016;35:2583–2591.
   PubMed Web of Science ®Google Scholar
• Li G, Yang F, Gu S, et al. MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C. Mol Med Rep. 2016;13:572–578.
   PubMed Web of Science ®Google Scholar
• Liu K, Qian T, Tang L, et al. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol. 2012;10:225.
   PubMed Web of Science ®Google Scholar
• Yang X, Cai H, Liang Y, et al. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. Oncol Rep. 2015;33:1723–1730.
   PubMed Web of Science ®Google Scholar
• Liu DX, Sun Q, Liang S, et al. MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. Mol Med Rep. 2013;7:642–648.
   PubMed Web of Science ®Google Scholar
• Huang DZ, Wang H, Liu R, et al. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2014;115:549–556.
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc Natl Acad Sci U S A. 2007;104:9667–9672.
   PubMed Web of Science ®Google Scholar
• Huang X, Le Q-T, Giaccia AJ. MiR-210–micromanager of the hypoxia pathway. Trends Mol Med. 2010;16:230–237.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. Prognostic markers in esophageal cancer: from basic research to clinical use. Expert Rev Gastroenterol Hepatol. 2015;9:887–889.
   PubMed Web of Science ®Google Scholar
• Marin JJ, Al-Abdulla R, Lozano E, et al. Mechanisms of resistance to chemotherapy in gastric cancer. Anticancer Agents Med Chem. 2016;16:318–334.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Lu Q, et al. Drug resistance-related microRNAs in esophageal cancer. Expert Opin Biol Ther. 2012;12:1487–1494.
   PubMed Web of Science ®Google Scholar
• Belian E, Kurucz R, Treue D, et al. Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. Anticancer Res. 2010;30:629–633.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu X, Li Z, et al. microRNA expression profiling in multidrug resistance of the 5Fuinduced SGC7901 human gastric cancer cell line. Mol Med Rep. 2013;7:1506–1510.
   PubMed Web of Science ®Google Scholar
• Wu G, Qin X-Q, Guo J-J, et al. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7:1449–1458.
   PubMed Web of Science ®Google Scholar
• Kim CH, Kim HK, Rettig RL, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. Bmc Med Genomics. 2011;4:79.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang L, Xia L, et al. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett. 2014;350:43–51.
   PubMed Web of Science ®Google Scholar
• Wu X-M, Shao X-Q, Meng X-X, et al. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin. 2011;32:259–269.
   PubMed Web of Science ®Google Scholar
• Riquelme I, Letelier P, Riffo-Campos AL, et al. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17:424.
   PubMed Web of Science ®Google Scholar
• Chen D, Zheng X, Kang D, et al. Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma. Med Princ Pract. 2012;21:68–73.
   PubMed Web of Science ®Google Scholar
• Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther. 2010;9:417–422.
   PubMed Web of Science ®Google Scholar
• Lim HJ, Crowe P, Yang J-L. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. 2015;141:671–689.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Yoshida T, Tsujioka M, et al. Autophagic cell death and cancer. Int J Mol Sci. 2014;15:3145–3153.
   PubMed Web of Science ®Google Scholar
• Lin Y, Nie Y, Zhao J, et al. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis. 2012;33:2377–2383.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang J-X, He Y-Q, et al. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis. 2014;5:e1197.
   PubMed Web of Science ®Google Scholar
• Yokota I, Sasaki Y, Kashima L, et al. Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene. Int J Oncol. 2010;37:1407–1416.
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081–2088.
   PubMed Web of Science ®Google Scholar
• Xie L, Jing R, Qi J, et al. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies. Blood Rev. 2015;29:33–44.
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069–1078.
   PubMed Web of Science ®Google Scholar
• Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996;272:408–411.
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Baba H, Izumi D, et al. Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation. Int J Cancer. 2016;138:1337–1349.
   PubMed Web of Science ®Google Scholar
• Wang F, Song X, Li X, et al. Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS One. 2013;8:e61792.
   PubMed Web of Science ®Google Scholar
• Arabpour M, Mohammadparast S, Maftouh M, et al. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in gastric cancer: current status and future perspectives. Curr Med Chem. 2016;23(36):4135–4150.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Meng X, Meng L, et al. Small indels induced by CRISPR/Cas9 in the 5’ region of microRNA lead to its depletion and Drosha processing retardance. RNA Biol. 2014;11:1243–1249.
   PubMed Web of Science ®Google Scholar